Based on the results of the Phase 1 trial of IMC-001, we are planning on conducting a Phase 2 trial to evaluate its efficacy in rare cancers in the second half of this year, stated Yun Jeong Song, CEO of ImmuneOncia. Moreover, we greatly appreciate those who supported us and for their contributions as the company successfully completed a Phase 1 trial of IMC-001. In collaboration with various institutions, we will continue our research and development of IMC-001 as well as the additional checkpoint immune-oncology molecules in our pipeline.
www.streetinsider.com/Corporate+News//...MC-001/15240186.html
www.streetinsider.com/Corporate+News//...MC-001/15240186.html
Werbung